Skip to main content

Find a trial

Find a trial

Trial status
Trial Phase
Trial type
45 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • INCB59872-101 A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies Solid tumors phase 1/2 Closed Any line Ahmad Hussein Awada
  • Intervention destinée aux parents L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité Solid tumors Open Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors
  • LUMINOSITY Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Lung phase 2 Closed Bogdan Grigoriu
  • LUNAR LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields(TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (avis 09/04/19) Multiple phase 3 Closed Stage IV NSCLC. Progression Under or after platinium regimen Thierry Berghmans
  • M18-868 A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868) Lung phase 3 Open Bogdan Grigoriu
  • MCLA-129-CL01 Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors Multiple phase 1/2 Open Mariana Brandao
  • MS201924-0022 An open-label, multicenter, phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor M1774 in combination wit cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies Lung phase 1b Open Mariana Brandao
  • Nivothym Single-arm, multicenter, phase II study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym) Thymus phase 2 Closed second line metastatic Thierry Berghmans
  • OX2016-203-01 An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Multiple phase 1 Closed Any line/RECIST v1.1/Eligible for platinium salt chemotherapy Nuria Kotecki
  • PACIFIC R First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy - PACIFIC Real World, PACIFIC-R NSCLC phase 4 Closed Advanced, recurrent, ou unresecable Ahmad Hussein Awada
  • PEARLS A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) NSCLC phase 3 Closed Adjuvant. ECOG 0 or 1 Thierry Berghmans
  • PM1183-B-005-14 A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Multiple phase 2 Closed brca 1/2 Ahmad Hussein Awada
  • PRECISION The Jules Bordet Institute Program for Molecular Profiling of Metastatic Lesions : Feasibility Multiple Closed Available tumor tissue Martine Piccart
  • SAFFRON A phase III, randomised, Open-Label study of Savolitinib in combination with Osimertinib versus platinium-based doublet chemotherapy in participants with EGFR mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who have progressed on treatment with Osimertinib Lung phase 3 Open Mariana Brandao